1. Home
  2. GMAB vs TLK Comparison

GMAB vs TLK Comparison

Compare GMAB & TLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$26.84

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Logo PT Telekomunikasi Indonesia Tbk

TLK

PT Telekomunikasi Indonesia Tbk

HOLD

Current Price

$16.64

Market Cap

18.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMAB
TLK
Founded
1999
1884
Country
Denmark
Indonesia
Employees
3029
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
16.9B
18.3B
IPO Year
N/A
2002

Fundamental Metrics

Financial Performance
Metric
GMAB
TLK
Price
$26.84
$16.64
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$39.81
N/A
AVG Volume (30 Days)
1.6M
621.0K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
6.08%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.85
$0.70
Revenue Next Year
$16.04
$3.00
P/E Ratio
$1.90
$15.71
Revenue Growth
N/A
N/A
52 Week Low
$18.89
$15.12
52 Week High
$35.43
$23.52

Technical Indicators

Market Signals
Indicator
GMAB
TLK
Relative Strength Index (RSI) 43.11 26.80
Support Level $24.95 N/A
Resistance Level $29.64 $19.10
Average True Range (ATR) 0.57 0.32
MACD -0.09 -0.14
Stochastic Oscillator 3.40 4.92

Price Performance

Historical Comparison
GMAB
TLK

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

About TLK PT Telekomunikasi Indonesia Tbk

PT Telkom Indonesia (Persero) Tbk is the integrated telecommunications provider in Indonesia. The company is focusing on dividing business into 3 Digital Business Domains namely, digital connectivity, digital platform, and digital services. It also provides a wide range of other communication services, including telephone network, interconnection services, multimedia, data and internet communication-related services, satellite transponder leasing, leased line, intelligent network and related services, cable television, and VoIP services. The group derives revenue from product lines: Mobile, Consumer, Enterprise, WIB and Others.

Share on Social Networks: